2481 related articles for article (PubMed ID: 19275278)
1. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
2. Amphotericin B formulations: a comparative review of efficacy and toxicity.
Hamill RJ
Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
[TBL] [Abstract][Full Text] [Related]
3. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.
Blyth CC; Hale K; Palasanthiran P; O'Brien T; Bennett MH
Cochrane Database Syst Rev; 2010 Feb; 2010(2):CD006343. PubMed ID: 20166083
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
Tiphine M; Letscher-Bru V; Herbrecht R
Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
6. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.
Scott LJ
Drugs; 2012 Nov; 72(16):2141-65. PubMed ID: 23083111
[TBL] [Abstract][Full Text] [Related]
7. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
8. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Keating G; Figgitt D
Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
[TBL] [Abstract][Full Text] [Related]
10. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
11. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
[TBL] [Abstract][Full Text] [Related]
12. Liposomal amphotericin B: what is its role in 2008?
Lanternier F; Lortholary O
Clin Microbiol Infect; 2008 May; 14 Suppl 4():71-83. PubMed ID: 18430132
[TBL] [Abstract][Full Text] [Related]
13. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
[TBL] [Abstract][Full Text] [Related]
15. Amphotericin B colloidal dispersion.
Patel R
Expert Opin Pharmacother; 2000 Mar; 1(3):475-88. PubMed ID: 11249532
[TBL] [Abstract][Full Text] [Related]
16. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
17. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.
Boogaerts M; Winston DJ; Bow EJ; Garber G; Reboli AC; Schwarer AP; Novitzky N; Boehme A; Chwetzoff E; De Beule K;
Ann Intern Med; 2001 Sep; 135(6):412-22. PubMed ID: 11560454
[TBL] [Abstract][Full Text] [Related]
18. Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Min WS; Shin WS
Korean J Intern Med; 2006 Sep; 21(3):165-72. PubMed ID: 17017665
[TBL] [Abstract][Full Text] [Related]
19. Caspofungin: in pediatric patients with fungal infections.
Garnock-Jones KP; Keam SJ
Paediatr Drugs; 2009; 11(4):259-69. PubMed ID: 19566110
[TBL] [Abstract][Full Text] [Related]
20. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]